Neoadjuvant therapy reduces node positivity but does not confer survival benefit versus up‐front resection for resectable intrahepatic cholangiocarcinoma: A propensity‐matched analysis
Open Access
- 31 July 2024
- journal article
- research article
- Published by Wiley in Journal of Surgical Oncology
- Vol. 130 (3) , 453-461
Abstract
Background: Neoadjuvant systemic therapy (NAST) is a treatment option for intrahepatic cholangiocarcinoma (iCCA), though its impact on short‐term oncologic outcomes and long‐term survival remains relatively unknown.Methods: The National Cancer Database (NCDB) between 2004 and 2019 was queried for patients with reportedly resectable (Stage I−IIIB) iCCA who received curative‐intent resection with lymphadenectomy. Propensity matching was performed between groups based on the use of NAST and groups were compared for overall survival (OS) and oncologic outcomes, including nodal harvest, rate of node positivity, rate of positive margins, and administration of adjuvant therapy.Results: Two thousand and five hundred ninety‐six patients met inclusion criteria; 364 (14%) received NAST versus 1763 (68%) up‐front resection. After matching, 332 pairs of patients were matched between NAST and no NAST. Patients receiving NAST had a greater nodal harvest (OR = 1.26 [1.09−1.88]; p < 0.001) and a lower rate of node positivity (OR = 0.67 [0.49−0.63]; p < 0.001). Patients without NAST were more likely to complete adjuvant systemic therapy (OR = 0.45 [0.33−0.62]; p < 0.001). However, patients receiving NAST had no OS benefit after resection compared to those who did not receive NAST (median OS 48.3 ± 5.3 vs. 38.8 ± 3.7 months; p = 0.160). Node‐positive disease (OR = 2.10 [1.78−2.45]; p < 0.001) conferred the greatest risk for reduced OS followed by positive‐margin resection (OR = 1.42 [1.21−1.47]; p < 0.001) and increasing T‐stage (OR = 1.34 [1.21−1.47]; p < 0.001).Conclusion: NAST for iCCA was associated with improved quality of oncologic resection but did not confer an OS benefit versus up‐front resection.Keywords
This publication has 18 references indexed in Scilit:
- Efficacy and safety comparison of neoadjuvant chemotherapy followed by surgery and upfront surgery for treating intrahepatic cholangiocarcinoma: a systematic review and meta-analysisBMC Gastroenterology, 2023
- Neoadjuvant therapy for cholangiocarcinoma: A comprehensive literature reviewCancer Treatment and Research Communications, 2021
- Very Early Recurrence After Liver Resection for Intrahepatic CholangiocarcinomaJAMA Surgery, 2020
- Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 studyThe Lancet Oncology, 2019
- Adjuvant Therapy for Resected Biliary Tract Cancer: ASCO Clinical Practice GuidelineJournal of Clinical Oncology, 2019
- Neoadjuvant chemotherapy for initially unresectable intrahepatic cholangiocarcinomaBritish Journal of Surgery, 2017
- Treatment and Prognosis for Patients With Intrahepatic CholangiocarcinomaJAMA Surgery, 2014
- Temporal trends in liver-directed therapy of patients with intrahepatic cholangiocarcinoma in the United States: A population-based analysisJournal of Surgical Oncology, 2014
- Neither Neoadjuvant nor Adjuvant Therapy Increases Survival After Biliary Tract Cancer Resection with Wide Negative MarginsJournal of Gastrointestinal Surgery, 2012
- Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract CancerNew England Journal of Medicine, 2010